0.71
price down icon7.29%   -0.0558
after-market After Hours: .70 -0.01 -1.41%
loading
Cytomx Therapeutics Inc stock is traded at $0.71, with a volume of 715.40K. It is down -7.29% in the last 24 hours and up +15.43% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$0.7658
Open:
$0.7695
24h Volume:
715.40K
Relative Volume:
0.41
Market Cap:
$60.07M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-35.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+8.23%
1M Performance:
+15.43%
6M Performance:
-31.07%
1Y Performance:
-55.62%
1-Day Range:
Value
$0.7044
$0.7696
1-Week Range:
Value
$0.6481
$0.78
52-Week Range:
Value
$0.40
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Name
Cytomx Therapeutics Inc
Name
Phone
650.515.3185
Name
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Employee
121
Name
Twitter
@cytomxinc
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
0.71 60.07M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-14-25 Resumed Piper Sandler Overweight
May-28-24 Upgrade Piper Sandler Neutral → Overweight
May-09-24 Upgrade Wedbush Neutral → Outperform
May-06-24 Upgrade Jefferies Hold → Buy
Apr-22-24 Upgrade JP Morgan Underweight → Neutral
Nov-14-22 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-07-22 Downgrade Jefferies Buy → Hold
Jul-07-22 Downgrade Mizuho Buy → Neutral
Jul-07-22 Downgrade Piper Sandler Overweight → Neutral
Jul-07-22 Downgrade Wedbush Outperform → Neutral
Jun-24-22 Initiated BMO Capital Markets Outperform
Jan-18-22 Upgrade Barclays Underweight → Overweight
Nov-15-21 Initiated BTIG Research Buy
May-28-21 Downgrade Barclays Equal Weight → Underweight
Mar-29-21 Initiated JP Morgan Overweight
Mar-23-21 Upgrade Jefferies Hold → Buy
Sep-22-20 Downgrade Guggenheim Buy → Neutral
Jun-01-20 Downgrade Jefferies Buy → Hold
May-14-20 Reiterated H.C. Wainwright Buy
Mar-24-20 Upgrade Wedbush Neutral → Outperform
Mar-04-20 Initiated Barclays Equal Weight
Nov-20-19 Initiated Guggenheim Buy
Nov-11-19 Downgrade Wedbush Outperform → Neutral
Jun-13-19 Initiated Mizuho Buy
May-14-19 Initiated Cantor Fitzgerald Overweight
Mar-11-19 Initiated Barclays Overweight
Nov-26-18 Initiated Piper Jaffray Overweight
Oct-15-18 Initiated Goldman Neutral
Sep-13-18 Initiated H.C. Wainwright Buy
Jun-01-18 Initiated SunTrust Buy
Jan-05-18 Initiated Citigroup Buy
Sep-08-17 Initiated Wedbush Outperform
Mar-27-17 Initiated H.C. Wainwright Buy
Mar-02-17 Initiated Instinet Buy
Jan-03-17 Downgrade Oppenheimer Outperform → Perform
Nov-02-15 Initiated Oppenheimer Outperform
View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

pulisher
10:30 AM

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research

10:30 AM
pulisher
Apr 24, 2025

Should investors be concerned about CytomX Therapeutics Inc (CTMX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

CytomX Therapeutics Inc (CTMX)’s Market Momentum: Closing Strong at 0.73, Down -0.80 - DWinneX

Apr 24, 2025
pulisher
Apr 22, 2025

CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com

Apr 22, 2025
pulisher
Apr 15, 2025

CytomX Therapeutics (NASDAQ:CTMX) Now Covered by Piper Sandler - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Piper Sandler sets CytomX stock target at $2.50, rates Overweight By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX) - The Globe and Mail

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler sets CytomX stock target at $2.50, rates Overweight - Investing.com

Apr 14, 2025
pulisher
Apr 12, 2025

New Outlook On CytomX Therapeutics Inc - stocksregister.com

Apr 12, 2025
pulisher
Apr 12, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 09, 2025

CytomX Therapeutics Inc (NASDAQ: CTMX) 5.47% Incline Turns Investors Away - stocksregister.com

Apr 09, 2025
pulisher
Apr 05, 2025

Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter

Apr 01, 2025
pulisher
Mar 26, 2025

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN

Mar 26, 2025
pulisher
Mar 23, 2025

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN

Mar 23, 2025
pulisher
Mar 21, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 20, 2025

Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 13, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 10, 2025

Cytomx Therapeutics Inc Stock (CTMX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):